Solventum Corporation
NYSE:SOLVMedical - Care Facilities
-$2.00 today
- Market cap
- $14.70B
- Beta
- 0.75
- P/E (TTM)
- 9.1
- EPS (TTM)
- $8.22
Volume 0.76M
Average 1.70M
SOLV Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Solventum CorporationNYSE: SOLV
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income grows, but more slowly than its trailing trend
Q2 FY2026 net income of $92M rose 2.2% year over year, behind the +277.4% change in trailing-twelve-month net income. Sequentially, it rose 607.7% from the prior quarter. Over 3 fiscal years it compounded at +5.0% a year.
Context
- Net income amounted to 18.7% of revenue in FY2025, up 12.9 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of $1.25B (-19.4%) for the fiscal year ending Dec 2026, a slowdown from the +224.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $92M+607.7% QoQ
- Last fiscal yearDec 2025
- $1.56B+224.8% YoY
- LTMJun 2026
- $1.43B+277.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.2% | -81.9% | -84.1 pp |
| 1 year | +224.8% | -19.4% | -244.3 pp |
| 3-year CAGR | +5.0% | -2.7% | -7.8 pp |
| 5-year CAGR | +4.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 1.56B USD
- Year-over-year change
- +224.8%
- 4-year CAGR
- +1.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.56B | +224.8% |
| FY2024 | 2024-12-31 | 479M | -64.4% |
| FY2023 | 2023-12-31 | 1.35B | +0.2% |
| FY2022 | 2022-12-31 | 1.34B | -8.0% |
| FY2021 | 2021-12-31 | 1.46B | — |
Net Income vs competitors
How SOLV compares with its peers on the latest reported figures
- SOLV's LTM Jun 2026 net income of $1.43B is the largest of the 10 companies compared; the peer median is $30.09M.
- Its year-over-year change of +277.4% is the 3rd highest of 10, against a peer median of +5.5%.
- Net income amounts to 17.3% of revenue for SOLV, versus a peer median of 8.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.43B | +277.4% | +5.0% | 17.3% | |
| LTM Sep 2026 | $1.22B | -27.5% | -9.2% | 6.0% | |
| LTM Jun 2026 | $975M | +304.6% | -32.5% | 8.5% | |
| LTM Oct 2026 | $633.6M | +4041.2% | -42.2% | 22.0% | |
| LTM Mar 2026 | $627M | -30.9% | -14.3% | 17.0% | |
| LTM Jun 2026 | $424M | +5.5% | -11.1% | 3.1% | |
| LTM Sep 2026 | $160.12M | +35.2% | +19.9% | 9.9% | |
| LTM Jul 2026 | $45.4M | -111.1% | -1.0% | 1.1% | |
| LTM Jun 2026 | $30.09M | +181.4% | — | 1.4% | |
| LTM Mar 2026 | $10.85M | -16.3% | -11.8% | 28.9% | |
| Peer median (excluding SOLV) | $30.09M | +5.5% | -11.5% | 8.5% | |
Competitors are the stored peer set for SOLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.46B | 1.34B | 1.35B | 479M | 1.56B |
| Depreciation & Amortization | 597M | 578M | 561M | 555M | 489M |
| Deferred Income Tax | (34M) | (141M) | (142M) | (155M) | (120M) |
| Stock-Based Compensation | 38M | 37M | 39M | 112M | 161M |
| Change in Working Capital | 67M | (202M) | 126M | 160M | (119M) |
| Accounts Receivables | (1M) | (32M) | (129M) | 276M | 78M |
| Inventory | (136M) | (82M) | 23M | (132M) | (139M) |
| Accounts Payables | 68M | 25M | 105M | 266M | 104M |
| Other Working Capital | 136M | (113M) | 127M | (250M) | (162M) |
| Other Non-Cash Items | 74M | 64M | (15M) | 34M | (1.6B) |
| Operating Cash Flow | 2.2B | 1.68B | 1.92B | 1.19B | 369M |
| Capital Expenditures | (277M) | (251M) | (290M) | (380M) | (379M) |
| Acquisitions (Net) | 0 | 0 | 60M | 0 | (696M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (1M) | (2M) | 0 | 0 | 3.87B |
| Investing Cash Flow | (278M) | (253M) | (230M) | (380M) | 2.8B |
| Debt Repayment | 0 | 0 | 0 | 8B | (3.07B) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.96B) | (1.46B) | (1.55B) | (8.24B) | 13M |
| Financing Cash Flow | (1.96B) | (1.46B) | (1.55B) | (240M) | (3.06B) |
| Effect of Forex Changes | 3M | 4M | 0 | 3M | 7M |
| Net Change in Cash | (33M) | (30M) | 133M | 568M | 116M |
| Free Cash Flow | 1.93B | 1.43B | 1.63B | 805M | (10M) |
Solventum Corporation
NYSE:SOLV
Intrinsic Alpha fair value
Locked
Current Price
$86.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.